FDA Advisory Committee Votes in Favor of Johnson & Johnson and Bristol Myers Squibb CAR-T Therapies
Silver Spring, Maryland – FDA’s Oncologic Drugs Advisory Committee recently voted to support the approvals of CAR-T therapies – Johnson & Johnson and Legend Biotech’s Carvykti and Bristol Myers Squibb and 2seventyBio’s Abcema – as earlier lines of treatment for multiple myeloma. The committee’s decision came after discussing the risks of early death in the … Read more